Literature DB >> 28040204

Molecular approaches for classifying endometrial carcinoma.

Josep M Piulats1, Esther Guerra2, Marta Gil-Martín1, Berta Roman-Canal3, Sonia Gatius3, Rebeca Sanz-Pamplona4, Ana Velasco3, August Vidal2, Xavier Matias-Guiu5.   

Abstract

Endometrial carcinoma is the most common cancer of the female genital tract. This review article discusses the usefulness of molecular techniques to classify endometrial carcinoma. Any proposal for molecular classification of neoplasms should integrate morphological features of the tumors. For that reason, we start with the current histological classification of endometrial carcinoma, by discussing the correlation between genotype and phenotype, and the most significant recent improvements. Then, we comment on some of the possible flaws of this classification, by discussing also the value of molecular pathology in improving them, including interobserver variation in pathologic interpretation of high grade tumors. Third, we discuss the importance of applying TCGA molecular approach to clinical practice. We also comment on the impact of intratumor heterogeneity in classification, and finally, we will discuss briefly, the usefulness of TCGA classification in tailoring immunotherapy in endometrial cancer patients. We suggest combining pathologic classification and the surrogate TCGA molecular classification for high-grade endometrial carcinomas, as an option to improve assessment of prognosis.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apoptosis; Beta-catenin; Chromosomal instability; E-cadherin; Endometrial carcinoma; Genetics; K-RAS; Microsatellite instability; PIK3CA; PTEN; TP53

Mesh:

Substances:

Year:  2016        PMID: 28040204     DOI: 10.1016/j.ygyno.2016.12.015

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  58 in total

1.  Hypoxia-induced PLOD2 regulates invasion and epithelial-mesenchymal transition in endometrial carcinoma cells.

Authors:  Junhui Wan; Junli Qin; Qinyue Cao; Ping Hu; Chunmei Zhong; Chunhua Tu
Journal:  Genes Genomics       Date:  2019-12-23       Impact factor: 1.839

2.  L1CAM expression in uterine carcinosarcoma is limited to the epithelial component and may be involved in epithelial-mesenchymal transition.

Authors:  Mac Versluis; A Plat; M de Bruyn; X Matias-Guiu; J Trovic; C Krakstad; H W Nijman; T Bosse; G H de Bock; H Hollema
Journal:  Virchows Arch       Date:  2018-08-23       Impact factor: 4.064

Review 3.  The evolution of endometrial carcinoma classification through application of immunohistochemistry and molecular diagnostics: past, present and future.

Authors:  Emily A Goebel; August Vidal; Xavier Matias-Guiu; C Blake Gilks
Journal:  Virchows Arch       Date:  2017-12-12       Impact factor: 4.064

4.  Restoration of microRNA-29c in type I endometrioid cancer reduced endometrial cancer cell growth.

Authors:  Michelle Van Sinderen; Meaghan Griffiths; Ellen Menkhorst; Keith Niven; Evdokia Dimitriadis
Journal:  Oncol Lett       Date:  2019-07-09       Impact factor: 2.967

5.  Knockdown of differentiation antagonizing non-protein coding RNA exerts anti-tumor effect by up-regulating miR-214 in endometrial carcinoma.

Authors:  Jingli Sun; Shaofeng Gao; Cuihua Lu
Journal:  Mol Cell Biochem       Date:  2019-06-03       Impact factor: 3.396

6.  Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.

Authors:  Tjalling Bosse; Remi A Nout; Jessica N McAlpine; Melissa K McConechy; Heidi Britton; Yaser R Hussein; Carlene Gonzalez; Raji Ganesan; Jane C Steele; Beth T Harrison; Esther Oliva; August Vidal; Xavier Matias-Guiu; Nadeem R Abu-Rustum; Douglas A Levine; C Blake Gilks; Robert A Soslow
Journal:  Am J Surg Pathol       Date:  2018-05       Impact factor: 6.394

7.  Reversal of obesity-driven aggressiveness of endometrial cancer by metformin.

Authors:  Hui Guo; Weimin Kong; Lu Zhang; Jianjun Han; Leslie H Clark; Yajie Yin; Ziwei Fang; Wenchuan Sun; Jiandong Wang; Timothy P Gilliam; Douglas Lee; Liza Makowski; Chunxiao Zhou; Victoria L Bae-Jump
Journal:  Am J Cancer Res       Date:  2019-10-01       Impact factor: 6.166

8.  Exploration of DNA methylation markers for diagnosis and prognosis of patients with endometrial cancer.

Authors:  Jianchao Ying; Teng Xu; Qian Wang; Jun Ye; Jianxin Lyu
Journal:  Epigenetics       Date:  2018-07-30       Impact factor: 4.528

9.  Nuclear receptor 4A1 (NR4A1) antagonists induce ROS-dependent inhibition of mTOR signaling in endometrial cancer.

Authors:  Kumaravel Mohankumar; Xi Li; Subhashree Sridharan; Keshav Karki; Stephen Safe
Journal:  Gynecol Oncol       Date:  2019-04-30       Impact factor: 5.482

Review 10.  Tackling tumor heterogeneity and phenotypic plasticity in cancer precision medicine: our experience and a literature review.

Authors:  Shijie Sheng; M Margarida Bernardo; Sijana H Dzinic; Kang Chen; Elisabeth I Heath; Wael A Sakr
Journal:  Cancer Metastasis Rev       Date:  2018-12       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.